3SBio (1530 HK): Global Index Inclusion as Stock Soars
3SBio could be added to a global index in August. There is large positioning in the stock, but industry momentum could lead to further upside in...
712 Views
Hang Seng Biotech Index Rebalance Preview: One Set of Changes in June
InSilico Medicine Cayman could replace Everest Medicines in the index in June. Estimated one-way turnover at the rebalance is 2.2% resulting in a...
300 Views
Primer: Everest Medicines (1952 HK) - Apr 2026
Everest Medicines is a biopharmaceutical company focused on developing and commercializing innovative therapies in Greater China and other Asia...
130 Views
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
103 Views
China Healthcare Weekly Wrap (22-26 June)
This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...
128 Views